---
title: "Bio-S: Subsidiary Saimo Pharmaceutical plans to win bids for 12 varieties in the 11th national drug procurement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264112516.md"
description: "Bio-S's subsidiary, Saimo Pharmaceutical, intends to win bids for 12 varieties in the 11th batch of national centralized drug procurement, demonstrating its production capacity and market competitiveness. Saimo Pharmaceutical has established GMP standard factories and laboratories, completed the landing verification of 617 projects, and registered 461 projects. This bidding win will accelerate its capacity release and further enhance its market share"
datetime: "2025-11-04T00:59:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264112516.md)
  - [en](https://longbridge.com/en/news/264112516.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264112516.md)
---

# Bio-S: Subsidiary Saimo Pharmaceutical plans to win bids for 12 varieties in the 11th national drug procurement

On November 3rd, Bio-S stated during a research visit by five institutions including Hongdao Investment and Yongquan Investment that its subsidiary, Saimo Pharmaceutical, has a construction area of approximately over 260 acres, with 163,000 square meters of GMP-standard pharmaceutical plants and supporting laboratories completed. A total of 617 projects have been verified for implementation, and 461 projects have been registered, ranking among the top in the country. In the 11th batch of national centralized drug procurement, Saimo Pharmaceutical has 12 varieties proposed for bidding, with 4 products as the marketing authorization holders and 8 products as the entrusted manufacturers. This proposed bidding demonstrates Saimo Pharmaceutical's production capacity and market competitiveness, and will accelerate the release of Saimo Pharmaceutical's production capacity in the future, further enhancing its market share

### Related Stocks

- [301096.CN](https://longbridge.com/en/quote/301096.CN.md)

## Related News & Research

- [Should You Be Adding Daewoong Pharmaceutical (KRX:069620) To Your Watchlist Today?](https://longbridge.com/en/news/286824214.md)
- [NorthPalm Capital Launches as AI-Augmented Investment Company | SCYRF Stock News](https://longbridge.com/en/news/286914222.md)
- [Elron says Axonius tops $200 million ARR, doubles revenue in two years](https://longbridge.com/en/news/287069566.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)
- [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md)